Cargando…

Real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK‐based electronic health records database

PURPOSE: We evaluated the reproducibility of a study characterizing newly‐diagnosed multiple myeloma (MM) patients within an electronic health records (EHR) database using different analytic tools. METHODS: We reproduced the findings of a descriptive cohort study using an iterative two‐phase approac...

Descripción completa

Detalles Bibliográficos
Autores principales: Seesaghur, Anouchka, Petruski‐Ivleva, Natalia, Banks, Victoria, Wang, Jocelyn Ruoyi, Mattox, Pattra, Hoeben, Edwin, Maskell, Joe, Neasham, David, Reynolds, Shannon L., Kafatos, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984077/
https://www.ncbi.nlm.nih.gov/pubmed/33174338
http://dx.doi.org/10.1002/pds.5171
_version_ 1783668000704954368
author Seesaghur, Anouchka
Petruski‐Ivleva, Natalia
Banks, Victoria
Wang, Jocelyn Ruoyi
Mattox, Pattra
Hoeben, Edwin
Maskell, Joe
Neasham, David
Reynolds, Shannon L.
Kafatos, George
author_facet Seesaghur, Anouchka
Petruski‐Ivleva, Natalia
Banks, Victoria
Wang, Jocelyn Ruoyi
Mattox, Pattra
Hoeben, Edwin
Maskell, Joe
Neasham, David
Reynolds, Shannon L.
Kafatos, George
author_sort Seesaghur, Anouchka
collection PubMed
description PURPOSE: We evaluated the reproducibility of a study characterizing newly‐diagnosed multiple myeloma (MM) patients within an electronic health records (EHR) database using different analytic tools. METHODS: We reproduced the findings of a descriptive cohort study using an iterative two‐phase approach. In Phase I, a common protocol and statistical analysis plan (SAP) were implemented by independent investigators using the Aetion Evidence Platform® (AEP), a rapid‐cycle analytics tool, and SAS statistical software as a gold standard for statistical analyses. Using the UK Clinical Practice Research Datalink (CPRD) dataset, the study included patients newly diagnosed with MM within primary care setting and assessed baseline demographics, conditions, drug exposure, and laboratory procedures. Phase II incorporated analysis revisions based on our initial comparison of the Phase I findings. Reproducibility of findings was evaluate by calculating the match rate and absolute difference in prevalence between the SAS and AEP study results. RESULTS: Phase I yielded slightly discrepant results, prompting amendments to SAP to add more clarity to operational decisions. After detailed specification of data and operational choices, exact concordance was achieved for the number of eligible patients (N = 2646), demographics, comorbidities (i.e., osteopenia, osteoporosis, cardiovascular disease [CVD], and hypertension), bone pain, skeletal‐related events, drug exposure, and laboratory investigations in the Phase II analyses. CONCLUSIONS: In this reproducibility study, a rapid‐cycle analytics tool and traditional statistical software achieved near‐exact findings after detailed specification of data and operational choices. Transparency and communication of the study design, operational and analytical choices between independent investigators were critical to achieve this reproducibility.
format Online
Article
Text
id pubmed-7984077
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-79840772021-03-24 Real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK‐based electronic health records database Seesaghur, Anouchka Petruski‐Ivleva, Natalia Banks, Victoria Wang, Jocelyn Ruoyi Mattox, Pattra Hoeben, Edwin Maskell, Joe Neasham, David Reynolds, Shannon L. Kafatos, George Pharmacoepidemiol Drug Saf Original Articles PURPOSE: We evaluated the reproducibility of a study characterizing newly‐diagnosed multiple myeloma (MM) patients within an electronic health records (EHR) database using different analytic tools. METHODS: We reproduced the findings of a descriptive cohort study using an iterative two‐phase approach. In Phase I, a common protocol and statistical analysis plan (SAP) were implemented by independent investigators using the Aetion Evidence Platform® (AEP), a rapid‐cycle analytics tool, and SAS statistical software as a gold standard for statistical analyses. Using the UK Clinical Practice Research Datalink (CPRD) dataset, the study included patients newly diagnosed with MM within primary care setting and assessed baseline demographics, conditions, drug exposure, and laboratory procedures. Phase II incorporated analysis revisions based on our initial comparison of the Phase I findings. Reproducibility of findings was evaluate by calculating the match rate and absolute difference in prevalence between the SAS and AEP study results. RESULTS: Phase I yielded slightly discrepant results, prompting amendments to SAP to add more clarity to operational decisions. After detailed specification of data and operational choices, exact concordance was achieved for the number of eligible patients (N = 2646), demographics, comorbidities (i.e., osteopenia, osteoporosis, cardiovascular disease [CVD], and hypertension), bone pain, skeletal‐related events, drug exposure, and laboratory investigations in the Phase II analyses. CONCLUSIONS: In this reproducibility study, a rapid‐cycle analytics tool and traditional statistical software achieved near‐exact findings after detailed specification of data and operational choices. Transparency and communication of the study design, operational and analytical choices between independent investigators were critical to achieve this reproducibility. John Wiley & Sons, Inc. 2020-11-21 2021-02 /pmc/articles/PMC7984077/ /pubmed/33174338 http://dx.doi.org/10.1002/pds.5171 Text en © 2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Seesaghur, Anouchka
Petruski‐Ivleva, Natalia
Banks, Victoria
Wang, Jocelyn Ruoyi
Mattox, Pattra
Hoeben, Edwin
Maskell, Joe
Neasham, David
Reynolds, Shannon L.
Kafatos, George
Real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK‐based electronic health records database
title Real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK‐based electronic health records database
title_full Real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK‐based electronic health records database
title_fullStr Real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK‐based electronic health records database
title_full_unstemmed Real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK‐based electronic health records database
title_short Real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK‐based electronic health records database
title_sort real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using clinical practice research datalink, a uk‐based electronic health records database
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984077/
https://www.ncbi.nlm.nih.gov/pubmed/33174338
http://dx.doi.org/10.1002/pds.5171
work_keys_str_mv AT seesaghuranouchka realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase
AT petruskiivlevanatalia realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase
AT banksvictoria realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase
AT wangjocelynruoyi realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase
AT mattoxpattra realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase
AT hoebenedwin realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase
AT maskelljoe realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase
AT neashamdavid realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase
AT reynoldsshannonl realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase
AT kafatosgeorge realworldreproducibilitystudycharacterizingpatientsnewlydiagnosedwithmultiplemyelomausingclinicalpracticeresearchdatalinkaukbasedelectronichealthrecordsdatabase